Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyHarmaline
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Harmaline
- Accession Number
- DB13875
- Type
- Small Molecule
- Groups
- Experimental
- Description
- Not Available
- Structure
Structure for DB13875 (Harmaline)
- Synonyms
- Not Available
- Product Ingredients
Ingredient UNII CAS InChI Key Harmaline hydrochloride 64056X913V 363-11-1 PULNGKOFHCQQQA-UHFFFAOYSA-N Harmaline hydrochloride dihydrate 5B4DGH2M9R 6027-98-1 LCEKUHFBUFUSSY-UHFFFAOYSA-N - Categories
- UNII
- CN58I4TOET
- CAS number
- 304-21-2
- Weight
- Average: 214.2631
Monoisotopic: 214.11061308 - Chemical Formula
- C13H14N2O
- InChI Key
- RERZNCLIYCABFS-UHFFFAOYSA-N
- InChI
- InChI=1S/C13H14N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-4,7,15H,5-6H2,1-2H3
- IUPAC Name
- 7-methoxy-1-methyl-3H,4H,9H-pyrido[3,4-b]indole
- SMILES
- COC1=CC2=C(C=C1)C1=C(N2)C(C)=NCC1
Pharmacology
- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UHistamine N-methyltransferase inhibitorHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Harmaline. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Harmaline. Experimental 3,4-Methylenedioxyamphetamine The risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Harmaline. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Harmaline. Experimental, Illicit 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Harmaline. Experimental Acarbose Harmaline may increase the hypoglycemic activities of Acarbose. Approved, Investigational Acebutolol Harmaline may increase the hypotensive activities of Acebutolol. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Alaproclate is combined with Harmaline. Experimental Albiglutide Harmaline may increase the hypoglycemic activities of Albiglutide. Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Harmaline. Approved, Illicit Aliskiren Harmaline may increase the hypotensive activities of Aliskiren. Approved, Investigational Almotriptan The serum concentration of Almotriptan can be increased when it is combined with Harmaline. Approved, Investigational Alogliptin Harmaline may increase the hypoglycemic activities of Alogliptin. Approved Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Harmaline. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Alphaprodine is combined with Harmaline. Illicit Alprenolol Harmaline may increase the hypotensive activities of Alprenolol. Approved, Withdrawn Altretamine Altretamine may increase the orthostatic hypotensive activities of Harmaline. Approved Ambrisentan Harmaline may increase the hypotensive activities of Ambrisentan. Approved, Investigational Amineptine Harmaline may increase the serotonergic activities of Amineptine. Illicit, Withdrawn Amitriptyline Harmaline may increase the serotonergic activities of Amitriptyline. Approved Amlodipine Harmaline may increase the hypotensive activities of Amlodipine. Approved Amoxapine Harmaline may increase the serotonergic activities of Amoxapine. Approved Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Harmaline. Approved, Illicit, Investigational Apomorphine The metabolism of Apomorphine can be decreased when combined with Harmaline. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Harmaline is combined with Apraclonidine. Approved Arbutamine The risk or severity of adverse effects can be increased when Harmaline is combined with Arbutamine. Approved Arformoterol The risk or severity of adverse effects can be increased when Harmaline is combined with Arformoterol. Approved, Investigational Atenolol Harmaline may increase the hypotensive activities of Atenolol. Approved Atomoxetine Harmaline may increase the central neurotoxic activities of Atomoxetine. Approved Atropine Harmaline may increase the hypertensive activities of Atropine. Approved, Vet Approved Bambuterol The risk or severity of adverse effects can be increased when Harmaline is combined with Bambuterol. Approved, Investigational Benazepril Harmaline may increase the hypotensive activities of Benazepril. Approved, Investigational Bendroflumethiazide Harmaline may increase the hypotensive activities of Bendroflumethiazide. Approved Benmoxin Benmoxin may increase the hypertensive activities of Harmaline. Withdrawn Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Harmaline. Approved, Illicit Bepridil Harmaline may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betahistine The serum concentration of Betahistine can be increased when it is combined with Harmaline. Approved, Investigational Betaxolol Harmaline may increase the hypotensive activities of Betaxolol. Approved, Investigational Bethanidine Harmaline may increase the hypotensive activities of Bethanidine. Approved Bezafibrate The risk or severity of adverse effects can be increased when Harmaline is combined with Bezafibrate. Approved, Investigational Bietaserpine Harmaline may increase the hypotensive activities of Bietaserpine. Experimental Bimatoprost Harmaline may increase the hypotensive activities of Bimatoprost. Approved, Investigational Bisoprolol Harmaline may increase the hypotensive activities of Bisoprolol. Approved Bosentan Harmaline may increase the hypotensive activities of Bosentan. Approved, Investigational BQ-123 Harmaline may increase the hypotensive activities of BQ-123. Investigational Bretylium Harmaline may increase the hypotensive activities of Bretylium. Approved Brimonidine The risk or severity of adverse effects can be increased when Harmaline is combined with Brimonidine. Approved Brofaromine Harmaline may increase the hypertensive activities of Brofaromine. Experimental Bromocriptine The metabolism of Bromocriptine can be decreased when combined with Harmaline. Approved, Investigational Bupranolol Harmaline may increase the hypotensive activities of Bupranolol. Approved Buprenorphine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Harmaline. Approved, Illicit, Investigational, Vet Approved Bupropion The risk or severity of adverse effects can be increased when Harmaline is combined with Bupropion. Approved Buspirone The risk or severity of adverse effects can be increased when Harmaline is combined with Buspirone. Approved, Investigational Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Harmaline. Approved, Illicit, Vet Approved Cabergoline The metabolism of Cabergoline can be decreased when combined with Harmaline. Approved Cadralazine Harmaline may increase the hypotensive activities of Cadralazine. Experimental Cafedrine Harmaline may increase the hypotensive activities of Cafedrine. Investigational Canagliflozin Harmaline may increase the hypoglycemic activities of Canagliflozin. Approved Candesartan Harmaline may increase the hypotensive activities of Candesartan. Experimental Candesartan cilexetil Harmaline may increase the hypotensive activities of Candesartan cilexetil. Approved Candoxatril Harmaline may increase the hypotensive activities of Candoxatril. Experimental Captopril Harmaline may increase the hypotensive activities of Captopril. Approved Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Harmaline. Approved, Investigational Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Harmaline. Illicit, Investigational, Vet Approved Caroxazone Caroxazone may increase the hypertensive activities of Harmaline. Withdrawn Carteolol Harmaline may increase the hypotensive activities of Carteolol. Approved Carvedilol Harmaline may increase the hypotensive activities of Carvedilol. Approved, Investigational Celiprolol Harmaline may increase the hypotensive activities of Celiprolol. Approved, Investigational Chlorothiazide Harmaline may increase the hypotensive activities of Chlorothiazide. Approved, Vet Approved Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Harmaline. Illicit, Withdrawn Chlorpropamide Harmaline may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Chlorthalidone Harmaline may increase the hypotensive activities of Chlorthalidone. Approved Cicletanine Harmaline may increase the hypotensive activities of Cicletanine. Investigational Cilazapril Harmaline may increase the hypotensive activities of Cilazapril. Approved Cirazoline Harmaline may increase the hypertensive activities of Cirazoline. Experimental Citalopram The risk or severity of adverse effects can be increased when Citalopram is combined with Harmaline. Approved Clemastine Harmaline may increase the anticholinergic activities of Clemastine. Approved, Investigational Clenbuterol The risk or severity of adverse effects can be increased when Harmaline is combined with Clenbuterol. Approved, Investigational, Vet Approved Clomipramine Harmaline may increase the serotonergic activities of Clomipramine. Approved, Investigational, Vet Approved Clonidine Harmaline may increase the hypotensive activities of Clonidine. Approved Cloranolol Harmaline may increase the hypotensive activities of Cloranolol. Experimental Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Harmaline. Approved, Illicit Cryptenamine Harmaline may increase the hypotensive activities of Cryptenamine. Approved Cyclobenzaprine Cyclobenzaprine may increase the serotonergic activities of Harmaline. Approved Cyclopenthiazide Harmaline may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclothiazide Harmaline may increase the hypotensive activities of Cyclothiazide. Approved Cyproheptadine Harmaline may increase the anticholinergic activities of Cyproheptadine. Approved Dapagliflozin Harmaline may increase the hypoglycemic activities of Dapagliflozin. Approved Dapoxetine The risk or severity of adverse effects can be increased when Dapoxetine is combined with Harmaline. Investigational Debrisoquin Harmaline may increase the hypotensive activities of Debrisoquin. Approved, Investigational Delapril Harmaline may increase the hypotensive activities of Delapril. Experimental Deserpidine Harmaline may increase the hypotensive activities of Deserpidine. Approved Desipramine Harmaline may increase the serotonergic activities of Desipramine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Harmaline. Approved, Investigational Deutetrabenazine The risk or severity of adverse effects can be increased when Harmaline is combined with Deutetrabenazine. Approved, Investigational Dexmethylphenidate Harmaline may increase the hypertensive activities of Dexmethylphenidate. Approved, Investigational Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Harmaline. Approved, Illicit Dextromethorphan Harmaline may increase the serotonergic activities of Dextromethorphan. Approved Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Harmaline. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Harmaline. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Harmaline. Approved, Investigational Diazoxide Harmaline may increase the hypotensive activities of Diazoxide. Approved Dibenzepin Harmaline may increase the serotonergic activities of Dibenzepin. Experimental Diethylnorspermine Harmaline may increase the hypotensive activities of Diethylnorspermine. Investigational Diethylpropion Harmaline may increase the hypertensive activities of Diethylpropion. Approved, Illicit Dihydralazine Harmaline may increase the hypotensive activities of Dihydralazine. Approved, Investigational Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Harmaline. Approved, Illicit Dihydroergotamine The metabolism of Dihydroergotamine can be decreased when combined with Harmaline. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Harmaline. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Harmaline. Experimental, Illicit Diltiazem Harmaline may increase the hypotensive activities of Diltiazem. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Harmaline. Approved, Illicit Dipivefrin The risk or severity of adverse effects can be increased when Harmaline is combined with Dipivefrin. Approved Disopyramide Harmaline may increase the hypoglycemic activities of Disopyramide. Approved Disulfiram The risk or severity of convulsion can be increased when Harmaline is combined with Disulfiram. Approved Dobutamine The risk or severity of adverse effects can be increased when Harmaline is combined with Dobutamine. Approved Domperidone The risk or severity of adverse effects can be increased when Harmaline is combined with Domperidone. Approved, Investigational, Vet Approved Dorzolamide Harmaline may increase the hypotensive activities of Dorzolamide. Approved Dosulepin Harmaline may increase the serotonergic activities of Dosulepin. Approved Doxapram Harmaline may increase the hypertensive activities of Doxapram. Approved, Vet Approved Doxazosin Harmaline may increase the hypotensive activities of Doxazosin. Approved Doxepin Harmaline may increase the serotonergic activities of Doxepin. Approved, Investigational Doxofylline The risk or severity of adverse effects can be increased when Harmaline is combined with Doxofylline. Approved, Investigational Doxylamine Harmaline may increase the anticholinergic activities of Doxylamine. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when DPDPE is combined with Harmaline. Experimental Drotebanol The risk or severity of adverse effects can be increased when Drotebanol is combined with Harmaline. Experimental, Illicit Droxidopa The risk or severity of adverse effects can be increased when Harmaline is combined with Droxidopa. Approved, Investigational Dulaglutide Harmaline may increase the hypoglycemic activities of Dulaglutide. Approved, Investigational Duloxetine The risk or severity of adverse effects can be increased when Duloxetine is combined with Harmaline. Approved Ecgonine The risk or severity of adverse effects can be increased when Ecgonine is combined with Harmaline. Experimental, Illicit Efonidipine Harmaline may increase the hypotensive activities of Efonidipine. Approved, Investigational Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Harmaline. Approved, Investigational Empagliflozin Harmaline may increase the hypoglycemic activities of Empagliflozin. Approved Enalapril Harmaline may increase the hypotensive activities of Enalapril. Approved, Vet Approved Enalaprilat Harmaline may increase the hypotensive activities of Enalaprilat. Approved Endralazine Harmaline may increase the hypotensive activities of Endralazine. Experimental Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Harmaline. Approved, Investigational Epanolol Harmaline may increase the hypotensive activities of Epanolol. Experimental Ephedra The risk or severity of adverse effects can be increased when Harmaline is combined with Ephedra. Approved, Nutraceutical, Withdrawn Epinephrine Harmaline may increase the hypertensive activities of Epinephrine. Approved, Vet Approved Epoprostenol Harmaline may increase the hypotensive activities of Epoprostenol. Approved Eprosartan Harmaline may increase the hypotensive activities of Eprosartan. Approved Ergotamine Harmaline may increase the hypertensive activities of Ergotamine. Approved Escitalopram The risk or severity of adverse effects can be increased when Escitalopram is combined with Harmaline. Approved, Investigational Esmirtazapine Harmaline may increase the serotonergic activities of Esmirtazapine. Investigational Etafedrine The risk or severity of adverse effects can be increased when Harmaline is combined with Etafedrine. Approved Ethanol The risk or severity of adverse effects can be increased when Ethanol is combined with Harmaline. Approved Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Harmaline. Approved, Illicit Etoperidone The risk or severity of adverse effects can be increased when Etoperidone is combined with Harmaline. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Harmaline. Illicit, Vet Approved Exenatide Harmaline may increase the hypoglycemic activities of Exenatide. Approved, Investigational Felodipine Harmaline may increase the hypotensive activities of Felodipine. Approved, Investigational Fenfluramine Harmaline may increase the serotonergic activities of Fenfluramine. Approved, Illicit, Investigational, Withdrawn Fenoldopam Harmaline may increase the hypotensive activities of Fenoldopam. Approved Fenoterol The risk or severity of adverse effects can be increased when Harmaline is combined with Fenoterol. Approved, Investigational Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Harmaline. Approved, Illicit, Investigational, Vet Approved Ferulic acid Harmaline may increase the hypotensive activities of Ferulic acid. Experimental Fluoxetine The risk or severity of adverse effects can be increased when Fluoxetine is combined with Harmaline. Approved, Vet Approved Fluvoxamine The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Harmaline. Approved, Investigational Formoterol The risk or severity of adverse effects can be increased when Harmaline is combined with Formoterol. Approved, Investigational Fosinopril Harmaline may increase the hypotensive activities of Fosinopril. Approved Frovatriptan The serum concentration of Frovatriptan can be increased when it is combined with Harmaline. Approved, Investigational Furazolidone Furazolidone may increase the hypertensive activities of Harmaline. Approved, Investigational, Vet Approved Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with Harmaline. Experimental Gliclazide Harmaline may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Harmaline may increase the hypoglycemic activities of Glimepiride. Approved Glipizide Harmaline may increase the hypoglycemic activities of Glipizide. Approved, Investigational Glyburide Harmaline may increase the hypoglycemic activities of Glyburide. Approved Guanabenz Harmaline may increase the hypotensive activities of Guanabenz. Approved, Investigational Guanadrel Harmaline may increase the hypotensive activities of Guanadrel. Approved Guanazodine Harmaline may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Harmaline may increase the hypotensive activities of Guanethidine. Approved Guanfacine Harmaline may increase the hypotensive activities of Guanfacine. Approved, Investigational Guanoclor Harmaline may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Harmaline may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Harmaline may increase the hypotensive activities of Guanoxan. Experimental Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Harmaline. Approved, Illicit, Investigational Hexamethonium Harmaline may increase the hypotensive activities of Hexamethonium. Experimental Hydracarbazine Hydracarbazine may increase the hypertensive activities of Harmaline. Experimental Hydralazine Harmaline may increase the hypotensive activities of Hydralazine. Approved Hydrochlorothiazide Harmaline may increase the hypotensive activities of Hydrochlorothiazide. Approved, Vet Approved Hydrocodone The risk or severity of adverse effects can be increased when Hydrocodone is combined with Harmaline. Approved, Illicit Hydroflumethiazide Harmaline may increase the hypotensive activities of Hydroflumethiazide. Approved, Investigational Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Harmaline. Approved, Illicit Hydroxyamphetamine The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Harmaline. Approved Imidapril Harmaline may increase the hypotensive activities of Imidapril. Investigational Imipramine Harmaline may increase the serotonergic activities of Imipramine. Approved Indacaterol The risk or severity of adverse effects can be increased when Harmaline is combined with Indacaterol. Approved Indalpine The risk or severity of adverse effects can be increased when Indalpine is combined with Harmaline. Investigational, Withdrawn Indapamide Harmaline may increase the hypotensive activities of Indapamide. Approved Indenolol Harmaline may increase the hypotensive activities of Indenolol. Withdrawn Indoramin Harmaline may increase the hypotensive activities of Indoramin. Withdrawn Insulin Aspart Harmaline may increase the hypoglycemic activities of Insulin Aspart. Approved Insulin Detemir Harmaline may increase the hypoglycemic activities of Insulin Detemir. Approved Insulin Glargine Harmaline may increase the hypoglycemic activities of Insulin Glargine. Approved Insulin Glulisine Harmaline may increase the hypoglycemic activities of Insulin Glulisine. Approved Insulin Human Harmaline may increase the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Lispro Harmaline may increase the hypoglycemic activities of Insulin Lispro. Approved Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Harmaline. Approved Iprindole Harmaline may increase the serotonergic activities of Iprindole. Experimental Iproclozide Iproclozide may increase the hypertensive activities of Harmaline. Withdrawn Iproniazid Iproniazid may increase the hypertensive activities of Harmaline. Withdrawn Irbesartan Harmaline may increase the hypotensive activities of Irbesartan. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypertensive activities of Harmaline. Approved Isoetarine The risk or severity of adverse effects can be increased when Harmaline is combined with Isoetarine. Approved Isometheptene The risk or severity of adverse effects can be increased when Harmaline is combined with Isometheptene. Approved Isoprenaline The risk or severity of adverse effects can be increased when Harmaline is combined with Isoprenaline. Approved, Investigational Isradipine Harmaline may increase the hypotensive activities of Isradipine. Approved, Investigational Ketanserin Harmaline may increase the hypotensive activities of Ketanserin. Investigational Ketobemidone The risk or severity of adverse effects can be increased when Ketobemidone is combined with Harmaline. Approved, Investigational L-Tryptophan The risk or severity of adverse effects can be increased when L-Tryptophan is combined with Harmaline. Approved, Nutraceutical, Withdrawn Labetalol Harmaline may increase the hypotensive activities of Labetalol. Approved Lacidipine Harmaline may increase the hypotensive activities of Lacidipine. Approved, Investigational Latanoprost Harmaline may increase the hypotensive activities of Latanoprost. Approved, Investigational Lercanidipine Harmaline may increase the hypotensive activities of Lercanidipine. Approved, Investigational Levodopa The risk or severity of adverse effects can be increased when Levodopa is combined with Harmaline. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Harmaline. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Harmaline. Approved, Investigational Levonordefrin Harmaline may increase the hypertensive activities of Levonordefrin. Approved Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Harmaline. Approved Levosalbutamol The risk or severity of adverse effects can be increased when Harmaline is combined with Levosalbutamol. Approved, Investigational Linezolid The risk or severity of adverse effects can be increased when Harmaline is combined with Linezolid. Approved, Investigational Linsidomine Harmaline may increase the hypotensive activities of Linsidomine. Experimental Liraglutide Harmaline may increase the hypoglycemic activities of Liraglutide. Approved Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Harmaline. Approved, Investigational Lisinopril Harmaline may increase the hypotensive activities of Lisinopril. Approved, Investigational Lisuride The metabolism of Lisuride can be decreased when combined with Harmaline. Approved, Investigational Lithium The risk or severity of adverse effects can be increased when Harmaline is combined with Lithium. Approved Lofentanil The risk or severity of adverse effects can be increased when Lofentanil is combined with Harmaline. Illicit Lofepramine Harmaline may increase the serotonergic activities of Lofepramine. Experimental Lofexidine Harmaline may increase the hypotensive activities of Lofexidine. Approved, Investigational Lorpiprazole The risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Harmaline. Approved Losartan Harmaline may increase the hypotensive activities of Losartan. Approved Macitentan Harmaline may increase the hypotensive activities of Macitentan. Approved Manidipine Harmaline may increase the hypotensive activities of Manidipine. Approved, Investigational Maprotiline The risk or severity of adverse effects can be increased when Harmaline is combined with Maprotiline. Approved, Investigational Mebanazine Mebanazine may increase the hypertensive activities of Harmaline. Withdrawn Mecamylamine Harmaline may increase the hypotensive activities of Mecamylamine. Approved, Investigational Mecasermin Harmaline may increase the hypoglycemic activities of Mecasermin. Approved, Investigational Mephedrone The risk or severity of adverse effects can be increased when Mephedrone is combined with Harmaline. Investigational Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with Harmaline. Approved Meptazinol The risk or severity of adverse effects can be increased when Meptazinol is combined with Harmaline. Experimental Mequitazine Harmaline may increase the anticholinergic activities of Mequitazine. Approved Metaraminol Harmaline may increase the hypertensive activities of Metaraminol. Approved, Investigational Metformin Harmaline may increase the hypoglycemic activities of Metformin. Approved Methadone The risk or severity of adverse effects can be increased when Harmaline is combined with Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Harmaline. Approved, Illicit Methamphetamine The risk or severity of adverse effects can be increased when Methamphetamine is combined with Harmaline. Approved, Illicit Methoserpidine Harmaline may increase the hypotensive activities of Methoserpidine. Experimental Methoxamine Harmaline may increase the hypertensive activities of Methoxamine. Approved, Investigational Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Harmaline. Experimental Methyldopa The risk or severity of hypertension can be increased when Harmaline is combined with Methyldopa. Approved Methylecgonine The risk or severity of adverse effects can be increased when Methylecgonine is combined with Harmaline. Experimental Methylene blue Harmaline may increase the serotonergic activities of Methylene blue. Approved, Investigational Methylphenidate Harmaline may increase the hypertensive activities of Methylphenidate. Approved, Investigational Metipranolol Harmaline may increase the hypotensive activities of Metipranolol. Approved Metolazone Harmaline may increase the hypotensive activities of Metolazone. Approved Metoprolol Harmaline may increase the hypotensive activities of Metoprolol. Approved, Investigational Metyrosine Harmaline may increase the hypotensive activities of Metyrosine. Approved Mianserin The risk or severity of adverse effects can be increased when Harmaline is combined with Mianserin. Approved, Investigational Mibefradil Harmaline may increase the hypotensive activities of Mibefradil. Investigational, Withdrawn Midodrine Harmaline may increase the hypertensive activities of Midodrine. Approved Midomafetamine The risk or severity of adverse effects can be increased when Midomafetamine is combined with Harmaline. Experimental, Illicit, Investigational Mifepristone Harmaline may increase the hypoglycemic activities of Mifepristone. Approved, Investigational Miglitol Harmaline may increase the hypoglycemic activities of Miglitol. Approved Milnacipran The risk or severity of adverse effects can be increased when Milnacipran is combined with Harmaline. Approved, Investigational Minaprine Minaprine may increase the hypertensive activities of Harmaline. Approved Minoxidil Harmaline may increase the hypotensive activities of Minoxidil. Approved, Investigational Mirtazapine The risk or severity of adverse effects can be increased when Harmaline is combined with Mirtazapine. Approved MMDA The risk or severity of adverse effects can be increased when MMDA is combined with Harmaline. Experimental, Illicit Moclobemide The risk or severity of adverse effects can be increased when Harmaline is combined with Moclobemide. Approved, Investigational Moexipril Harmaline may increase the hypotensive activities of Moexipril. Approved Morphine The therapeutic efficacy of Morphine can be increased when used in combination with Harmaline. Approved, Investigational Moxonidine Harmaline may increase the hypotensive activities of Moxonidine. Approved, Investigational Muzolimine Harmaline may increase the hypotensive activities of Muzolimine. Experimental Nadolol Harmaline may increase the hypotensive activities of Nadolol. Approved Naftopidil Harmaline may increase the hypotensive activities of Naftopidil. Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Harmaline. Approved Naluzotan The metabolism of Naluzotan can be decreased when combined with Harmaline. Investigational Naratriptan The serum concentration of Naratriptan can be increased when it is combined with Harmaline. Approved, Investigational Nateglinide Harmaline may increase the hypoglycemic activities of Nateglinide. Approved, Investigational Nebivolol Harmaline may increase the hypotensive activities of Nebivolol. Approved, Investigational Nefazodone The risk or severity of adverse effects can be increased when Nefazodone is combined with Harmaline. Approved, Withdrawn Nialamide Nialamide may increase the hypertensive activities of Harmaline. Withdrawn Nicardipine Harmaline may increase the hypotensive activities of Nicardipine. Approved, Investigational Nicorandil Harmaline may increase the hypotensive activities of Nicorandil. Approved, Investigational Niguldipine Harmaline may increase the hypotensive activities of Niguldipine. Experimental Nilvadipine Harmaline may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimodipine Harmaline may increase the hypotensive activities of Nimodipine. Approved, Investigational Nisoldipine Harmaline may increase the hypotensive activities of Nisoldipine. Approved Nitrendipine Harmaline may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nitroprusside Harmaline may increase the hypotensive activities of Nitroprusside. Approved, Investigational Norepinephrine Harmaline may increase the hypertensive activities of Norepinephrine. Approved Normethadone The risk or severity of adverse effects can be increased when Normethadone is combined with Harmaline. Approved, Illicit Nortriptyline Harmaline may increase the serotonergic activities of Nortriptyline. Approved Octamoxin Octamoxin may increase the hypertensive activities of Harmaline. Withdrawn Olanzapine Harmaline may increase the serotonergic activities of Olanzapine. Approved, Investigational Olmesartan Harmaline may increase the hypotensive activities of Olmesartan. Approved, Investigational Olodaterol The risk or severity of adverse effects can be increased when Harmaline is combined with Olodaterol. Approved Omapatrilat Harmaline may increase the hypotensive activities of Omapatrilat. Investigational Opipramol Harmaline may increase the serotonergic activities of Opipramol. Investigational Opium The risk or severity of adverse effects can be increased when Opium is combined with Harmaline. Approved, Illicit Orciprenaline The risk or severity of adverse effects can be increased when Harmaline is combined with Orciprenaline. Approved Oxprenolol Harmaline may increase the hypotensive activities of Oxprenolol. Approved Oxycodone The risk or severity of adverse effects can be increased when Harmaline is combined with Oxycodone. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Harmaline. Approved, Investigational, Vet Approved Pargyline Pargyline may increase the hypertensive activities of Harmaline. Approved Paroxetine The risk or severity of adverse effects can be increased when Paroxetine is combined with Harmaline. Approved, Investigational Penbutolol Harmaline may increase the hypotensive activities of Penbutolol. Approved, Investigational Pentamidine Harmaline may increase the hypoglycemic activities of Pentamidine. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Harmaline. Approved, Vet Approved Pentolinium Harmaline may increase the hypotensive activities of Pentolinium. Approved Pergolide The metabolism of Pergolide can be decreased when combined with Harmaline. Approved, Investigational, Vet Approved, Withdrawn Perindopril Harmaline may increase the hypotensive activities of Perindopril. Approved Pethidine Harmaline may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine. Approved Phenazocine The risk or severity of adverse effects can be increased when Phenazocine is combined with Harmaline. Experimental Phenelzine Phenelzine may increase the hypertensive activities of Harmaline. Approved Pheniprazine Pheniprazine may increase the hypertensive activities of Harmaline. Withdrawn Phenoperidine The risk or severity of adverse effects can be increased when Phenoperidine is combined with Harmaline. Experimental Phenoxybenzamine Harmaline may increase the hypotensive activities of Phenoxybenzamine. Approved Phenoxypropazine Phenoxypropazine may increase the hypertensive activities of Harmaline. Withdrawn Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Harmaline. Approved, Illicit Phentolamine Harmaline may increase the hypotensive activities of Phentolamine. Approved Phenylephrine Harmaline may increase the hypertensive activities of Phenylephrine. Approved Phenylpropanolamine The risk or severity of adverse effects can be increased when Harmaline is combined with Phenylpropanolamine. Approved, Vet Approved, Withdrawn Pholcodine Pholcodine may increase the serotonergic activities of Harmaline. Approved, Illicit Piclozotan The metabolism of Piclozotan can be decreased when combined with Harmaline. Investigational Pinacidil Harmaline may increase the hypotensive activities of Pinacidil. Approved Pindolol Harmaline may increase the hypotensive activities of Pindolol. Approved, Investigational Pioglitazone Harmaline may increase the hypoglycemic activities of Pioglitazone. Approved, Investigational Pirbuterol The risk or severity of adverse effects can be increased when Harmaline is combined with Pirbuterol. Approved Piritramide The risk or severity of adverse effects can be increased when Piritramide is combined with Harmaline. Approved, Investigational Pirlindole Pirlindole may increase the hypertensive activities of Harmaline. Approved Pivhydrazine Pivhydrazine may increase the hypertensive activities of Harmaline. Withdrawn Pizotifen Harmaline may increase the anticholinergic activities of Pizotifen. Approved Platelet Activating Factor Harmaline may increase the hypotensive activities of Platelet Activating Factor. Experimental Polythiazide Harmaline may increase the hypotensive activities of Polythiazide. Approved Pramlintide Harmaline may increase the hypoglycemic activities of Pramlintide. Approved, Investigational Prazosin Harmaline may increase the hypotensive activities of Prazosin. Approved Procarbazine Harmaline may increase the hypertensive activities of Procarbazine. Approved, Investigational Procaterol The risk or severity of adverse effects can be increased when Harmaline is combined with Procaterol. Approved, Investigational Propranolol Harmaline may increase the hypotensive activities of Propranolol. Approved, Investigational Protokylol The risk or severity of adverse effects can be increased when Harmaline is combined with Protokylol. Approved, Vet Approved Protriptyline Harmaline may increase the serotonergic activities of Protriptyline. Approved Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Harmaline. Approved Quinapril Harmaline may increase the hypotensive activities of Quinapril. Approved, Investigational Quinine Harmaline may increase the hypoglycemic activities of Quinine. Approved Racepinephrine The risk or severity of adverse effects can be increased when Harmaline is combined with Racepinephrine. Approved Ramipril Harmaline may increase the hypotensive activities of Ramipril. Approved Rasagiline Rasagiline may increase the hypertensive activities of Harmaline. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Harmaline. Approved Remikiren Harmaline may increase the hypotensive activities of Remikiren. Approved Repaglinide Harmaline may increase the hypoglycemic activities of Repaglinide. Approved, Investigational Rescinnamine Harmaline may increase the hypotensive activities of Rescinnamine. Approved Reserpine The risk or severity of adverse effects can be increased when Harmaline is combined with Reserpine. Approved, Investigational Rilmenidine Harmaline may increase the hypotensive activities of Rilmenidine. Approved, Investigational Riociguat Harmaline may increase the hypotensive activities of Riociguat. Approved Ritobegron The risk or severity of adverse effects can be increased when Ritobegron is combined with Harmaline. Investigational Ritodrine The risk or severity of adverse effects can be increased when Harmaline is combined with Ritodrine. Approved, Investigational Rizatriptan The serum concentration of Rizatriptan can be increased when it is combined with Harmaline. Approved Ropinirole The metabolism of Ropinirole can be decreased when combined with Harmaline. Approved, Investigational Rosiglitazone Harmaline may increase the hypoglycemic activities of Rosiglitazone. Approved, Investigational Safrazine Safrazine may increase the hypertensive activities of Harmaline. Withdrawn Salbutamol The risk or severity of adverse effects can be increased when Harmaline is combined with Salbutamol. Approved, Vet Approved Salmeterol The risk or severity of adverse effects can be increased when Harmaline is combined with Salmeterol. Approved Saprisartan Harmaline may increase the hypotensive activities of Saprisartan. Experimental Saxagliptin Harmaline may increase the hypoglycemic activities of Saxagliptin. Approved Selegiline Selegiline may increase the hypertensive activities of Harmaline. Approved, Investigational, Vet Approved Selexipag Harmaline may increase the hypotensive activities of Selexipag. Approved Sertraline The risk or severity of adverse effects can be increased when Sertraline is combined with Harmaline. Approved Sitagliptin Harmaline may increase the hypoglycemic activities of Sitagliptin. Approved, Investigational Sitaxentan Harmaline may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Spirapril Harmaline may increase the hypotensive activities of Spirapril. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Harmaline. Approved, Investigational Sulfadiazine Harmaline may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole Harmaline may increase the hypoglycemic activities of Sulfamethoxazole. Approved Sulfisoxazole Harmaline may increase the hypoglycemic activities of Sulfisoxazole. Approved, Vet Approved Sumatriptan The serum concentration of Sumatriptan can be increased when it is combined with Harmaline. Approved, Investigational Sunitinib Harmaline may increase the hypoglycemic activities of Sunitinib. Approved, Investigational Talinolol Harmaline may increase the hypotensive activities of Talinolol. Investigational Tapentadol The risk or severity of adverse effects can be increased when Tapentadol is combined with Harmaline. Approved Telmisartan Harmaline may increase the hypotensive activities of Telmisartan. Approved, Investigational Temocapril Harmaline may increase the hypotensive activities of Temocapril. Experimental, Investigational Terbutaline The risk or severity of adverse effects can be increased when Harmaline is combined with Terbutaline. Approved Terlipressin Harmaline may increase the hypotensive activities of Terlipressin. Approved, Investigational Testosterone propionate The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Harmaline. Approved, Investigational, Vet Approved, Withdrawn Tetrabenazine The risk or severity of adverse effects can be increased when Harmaline is combined with Tetrabenazine. Approved, Investigational Tetrahydropalmatine Harmaline may increase the hypotensive activities of Tetrahydropalmatine. Investigational Tetryzoline Harmaline may increase the hypertensive activities of Tetryzoline. Approved Theodrenaline Harmaline may increase the hypotensive activities of Theodrenaline. Investigational Tianeptine The risk or severity of adverse effects can be increased when Tianeptine is combined with Harmaline. Approved, Investigational Tibolone Harmaline may increase the hypotensive activities of Tibolone. Approved, Investigational Ticrynafen Harmaline may increase the hypotensive activities of Ticrynafen. Withdrawn Tilidine The risk or severity of adverse effects can be increased when Tilidine is combined with Harmaline. Experimental Timolol Harmaline may increase the hypotensive activities of Timolol. Approved Tolazamide Harmaline may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolazoline Harmaline may increase the hypotensive activities of Tolazoline. Approved, Vet Approved Tolbutamide Harmaline may increase the hypoglycemic activities of Tolbutamide. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Harmaline. Approved, Withdrawn Tolonidine Harmaline may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypertensive activities of Harmaline. Approved Torasemide Harmaline may increase the hypotensive activities of Torasemide. Approved Tramadol Tramadol may increase the neuroexcitatory activities of Harmaline. Approved, Investigational Trandolapril Harmaline may increase the hypotensive activities of Trandolapril. Approved Tranylcypromine Tranylcypromine may increase the hypertensive activities of Harmaline. Approved, Investigational Travoprost Harmaline may increase the hypotensive activities of Travoprost. Approved Trazodone Harmaline may increase the serotonergic activities of Trazodone. Approved, Investigational Treprostinil Harmaline may increase the hypotensive activities of Treprostinil. Approved, Investigational Trichlormethiazide Harmaline may increase the hypotensive activities of Trichlormethiazide. Approved, Vet Approved Trimazosin Harmaline may increase the hypotensive activities of Trimazosin. Experimental Trimethaphan Harmaline may increase the hypotensive activities of Trimethaphan. Approved, Investigational Trimipramine Harmaline may increase the serotonergic activities of Trimipramine. Approved Unoprostone Harmaline may increase the hypotensive activities of Unoprostone. Approved, Investigational Urapidil Harmaline may increase the hypotensive activities of Urapidil. Investigational Valsartan Harmaline may increase the hypotensive activities of Valsartan. Approved, Investigational Venlafaxine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Harmaline. Approved Vilanterol The risk or severity of adverse effects can be increased when Harmaline is combined with Vilanterol. Approved Vilazodone The metabolism of Vilazodone can be decreased when combined with Harmaline. Approved Vincamine Harmaline may increase the hypotensive activities of Vincamine. Experimental Vinpocetine Harmaline may increase the hypotensive activities of Vinpocetine. Investigational Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Harmaline. Approved, Investigational Xipamide Harmaline may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Harmaline may increase the hypotensive activities of Xylometazoline. Approved, Investigational Zimelidine The risk or severity of adverse effects can be increased when Zimelidine is combined with Harmaline. Withdrawn Zofenopril Harmaline may increase the hypotensive activities of Zofenopril. Experimental Zolmitriptan The serum concentration of Zolmitriptan can be increased when it is combined with Harmaline. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0030310
- KEGG Compound
- C06536
- PubChem Compound
- 5280951
- PubChem Substance
- 347829327
- ChemSpider
- 10211258
- BindingDB
- 50029799
- ChEBI
- 28172
- ChEMBL
- CHEMBL340807
- Wikipedia
- Harmaline
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0576 mg/mL ALOGPS logP 2.61 ALOGPS logP 1.67 ChemAxon logS -3.6 ALOGPS pKa (Strongest Acidic) 14.95 ChemAxon pKa (Strongest Basic) 6.46 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 37.38 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 64.15 m3·mol-1 ChemAxon Polarizability 24.2 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-00di-2920000000-44473ef3fbb78c164b21
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as harmala alkaloids. These are compounds with a structure based on harmaline, harmine, harmalol, harman or a derivative of those parents. These parents are beta-carbolines, consisting of a pyrimidine fused to the pyrrole moiety of an indole to form a pyrido[3,4-b]indole.
- Kingdom
- Organic compounds
- Super Class
- Alkaloids and derivatives
- Class
- Harmala alkaloids
- Sub Class
- Not Available
- Direct Parent
- Harmala alkaloids
- Alternative Parents
- Beta carbolines / 3-alkylindoles / Anisoles / Alkyl aryl ethers / Pyrroles / Heteroaromatic compounds / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds show 1 more
- Substituents
- Harmaline / Harman / Beta-carboline / Pyridoindole / 3-alkylindole / Indole or derivatives / Indole / Anisole / Alkyl aryl ether / Benzenoid show 16 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- harmala alkaloid (CHEBI:28172) / Indole alkaloids (C06536) / an alkaloid (CPD-9939)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Histamine n-methyltransferase activity
- Specific Function
- Inactivates histamine by N-methylation. Plays an important role in degrading histamine and in regulating the airway response to histamine.
- Gene Name
- HNMT
- Uniprot ID
- P50135
- Uniprot Name
- Histamine N-methyltransferase
- Molecular Weight
- 33294.765 Da
References
- Cumming P, Vincent SR: Inhibition of histamine-N-methyltransferase (HNMT) by fragments of 9-amino-1,2,3,4-tetrahydroacridine (tacrine) and by beta-carbolines. Biochem Pharmacol. 1992 Sep 1;44(5):989-92. [PubMed:1530666]
Drug created on August 02, 2017 13:23 / Updated on May 20, 2018 05:43